Michael Rabinowitz - 03 Jan 2022 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Reporting relationship: Chief Commercial Officer
Issuer ticker: ORMP
Reported as of: 03 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2022, 19:38:10 UTC
Prior SEC filing: 30 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ Michael Rabinowitz

Key filing fact

Michael Rabinowitz filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 05 Jan 2022.

Key facts

This page summarizes Michael Rabinowitz's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2022, 19:38.

Change

Previous filing in this sequence was filed on 30 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORMP transaction

Common Stock

Award

Transaction value
Shares: +19,000
Change %: +21%
Price
Shares after: 109,468
Date: 03 Jan 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ORMP transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +32,000
Change %
Price: $0.000000
Shares after: 32,000
Date: 03 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,000
Exercise price: $13.89
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 4,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

Footnote F2

The Stock Option will vest in 4 installments as follows: 8,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.